2024-519491-60-00招募中2 期
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
Universitaetsklinikum Tuebingen AöR1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2026年7月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
ZKS Tübingen
Scientific
Universitaetsklinikum Tuebingen AöR
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid TumorsAdvanced Solid Tumors2025-524857-15-00BeOne Medicines I GmbH24
招募中
不适用
BG-C477-101Advanced Solid TumorsjRCT203125086018
招募中
不适用
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsAdvanced Solid TumorsjRCT203125067815
招募中
不适用
GNX1021-01Gastrointestinal cancerjRCT203126014164
尚未招募
1 期
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy SubjectsMultiple sclerosis2025-521754-41-00Immunic AG24